Brandon Miller

Also affiliated with Frederick National Laboratory for Cancer Research

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Atezolizumab for Advanced Alveolar Soft Part Sarcoma”.

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

New England Journal of Medicine(2023)10.1056/nejmoa2303383

N/A

3.3DataRank · unranked

158 citations

Elad Sharon, Geraldine O’Sullivan Coyne, Nancy Moore, Jared C. Foster, James Hu +26 more

Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04073-5

N/A

0.494DataRank · unranked

26 citations

Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer +18 more

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study

The Oncologist(2020)10.1634/theoncologist.2020-0039

N/A

0.406DataRank · unranked

14 citations

Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao, Ewa Mrózek +23 more

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3624

N/A

0.365DataRank · unranked

4 citations

Arjun Mittra, Geraldine O’Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar +15 more

Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3088

N/A

0.358DataRank · unranked

5 citations

Geraldine O’Sullivan Coyne, Naoko Takebe, Abdul Rafeh Naqash, Jessica Mukherjee, Ashley Bruns +12 more

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04600-0

N/A

0.314DataRank · unranked

6 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Larry Rubinstein +13 more

Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5564

N/A

0.145DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Mohamad A. Salkeni, Naoko Takebe, Ning Ma +12 more

Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3026

N/A

0.104DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Sarah Miller +15 more